Business Wire

H2SITE

12.6.2024 10:37:33 CEST | Business Wire | Press release

Share
H2SITE Builds the Most Efficient Ammonia Cracker to Produce Fuel-Cell Purity Hydrogen for the Ammogen Project in the UK

H2SITE has designed and constructed the most efficient ammonia cracker utilizing membrane reactor technology to produce fuel cell-grade hydrogen for the Ammogen Project located at Tyseley Energy Park (TEP). This innovative project will use ammonia to store hydrogen and convert it to hydrogen in one step. Ammonia is becoming the carrier of choice worldwide to transport hydrogen.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240612761636/en/

The system designed and assembled by H2SITE will produce 200 kg of green hydrogen per day. The hydrogen produced will be ready for mobility applications in the Birmingham area.
H2SITE's ammonia cracking and separation technology consists of the integration of H2-selective membranes immersed in a catalytic bed where ammonia is cracked into its products. As the reaction produces hydrogen, the technology separates the hydrogen in-situ through these membranes, eliminating the need for downstream separation units. The selective separation of hydrogen in H2SITE's membrane reactors results in virtually complete ammonia conversions at mild temperatures, with over 98% hydrogen recovery, always meeting fuel-cell grade standards.

"This project is a steppingstone for us, as it validates the technology of the membrane reactor for ammonia cracking. We plan to scale it up to process tons per day within the next two years for use in import hubs and maritime applications" according to Jose Medrano, Technical Director at H2SITE.

In collaboration with partners such as the Tyseley Energy Park (TEP), Department for Energy Security and Net Zero (DESNZ), Gemserv (Talan), EQUANS, Yara International, and the University of Birmingham, the Ammogen project aims to promote the international hydrogen trade.

About H2SITE H2SITE was created in 2020 and has an exclusive technology of reactors and separators for the conversion of different feedstocks into hydrogen, including ammonia, methanol, or syngas, in addition to the separation of hydrogen from gaseous mixtures in low concentration for applications in salt caverns or geologic hydrogen.

(www.h2site.eu)

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240612761636/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Dubai Culture Opens Registration for ISEA2026 Dubai26.10.2026 13:09:00 CET | Press release

Dubai Culture and Arts Authority (Dubai Culture) has opened registration for the 31st International Symposium on Electronic/Emerging Art (ISEA2026 Dubai), taking place from 6 to 15 November 2026 under the theme ‘ELYAH: Constellating Place, Data and Identity’. The symposium will be the largest edition to date, bringing together artists, researchers, and innovators from around the world to explore the intersection of art, science, and technology and exchange perspectives on the future of contemporary creative practice. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261026652826/en/ Dubai Culture Opens Registration for ISEA2026 Dubai (Graphic: AETOSWire) The event supports Dubai Culture’s efforts to advance the digital arts ecosystem, deliver on its Digital Arts Roadmap objectives, and empower local talent. It also reinforces Dubai’s position as a global cultural reference, a leader in innovation, a driver of the creative econo

Agendia Unveils Clinical Validation of AI-Driven Digital Pathology Approach26.10.2026 13:00:00 CET | Press release

The investigational AI-driven digital assay demonstrated high concordance with MammaPrint results in the prospective RASTER cohort of 372 early-stage breast cancer patients with a median follow-up of 10.3 years Agendia, Inc., a leader in precision oncology for breast cancer, recently presented research introducing its investigational artificial intelligence (AI)-driven digital pathology approach for the MammaPrint®70-gene recurrence signature at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid. The podium presentation, delivered by co-founder and Chief Research Officer, Laura van ’t Veer, Ph.D., detailed the development and clinical validation of a deep learning pipeline that can infer MammaPrint (MP) risk categories directly from hematoxylin and eosin (H&E)-stained, whole-slide images (WSIs). The company also presented two additional posters highlighting data from the prospective, real-world FLEX Study (NCT03053193). “AI has been part of Agendia’s scientific fo

C.H. Robinson Debuts Lean AI for Ocean Shipping, Air Freight and Customs26.10.2026 13:00:00 CET | Press release

Global logistic provider’s fleet of AI agents grows, bringing greater speed, precision and agility to supply chains around the world As the global leader in Lean AI, C.H. Robinson has launched new AI agents that perform work in ocean shipping, air freight and customs brokerage. They represent an expansion of the company’s Lean AI capabilities into freight forwarding, for the benefit of more customers, and into work so complex that a single shipping task can require over a dozen AI agents working in tandem. Continuing to disrupt itself and the industry, the company’s new tech brings substantial speed-to-market gains, precision and agility to customers’ supply chains without sacrificing human oversight or personal attention. The new tech includes: Price-quoting for ocean and air cargo: AI has determined and delivered over 80,000 price quotes for over 3,600 customers. Quotes that used to take a day for an air shipment and two to three days for an ocean shipment now take two to three minut

TVS Motor Company Returns to EICMA With New Models for Europe26.10.2026 12:45:00 CET | Press release

A year after its Milan debut, TVS Motor returns with a rapidly expanding European footprint and Italian sales up 110%Peyman Kargar to lead TVS Motor’s next phase of global growth as the company expands European footprint TVS Motor Company (TVSM), a global leader in two- and three-wheeler manufacturing, returns to EICMA in Milan this November, one year after its debut at the world’s largest two-wheeler exhibition. The company will present new models for Europe at a press conference on Tuesday, 3 November at 10:00 CET. The TVS stand is in Hall 18, Stand I64. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261026990290/en/ TVS Motor Company will present new models for Europe at a press conference on Tuesday, 3 November at 10:00 CET at EICMA this year. EICMA 2025 marked the beginning of TVS Motor's European growth journey. Since then, the company has focused on establishing the foundations for long-term success, building its deal

Two-Year Data of Pimicotinib Demonstrated Durable Tumor Control and Sustained Improvement in TGCT Symptoms and Joint Function26.10.2026 12:00:00 CET | Press release

Improvements in symptoms of pain, stiffness, and range of motion were sustained through two yearsTumor responses remained robust1 and durable2Not intended for U.K.-, U.S.- or Canada-based media Merck, a leading science and technology company, today announced new two-year follow-up results from the Phase 3 MANEUVER study evaluating pimicotinib in patients with tenosynovial giant cell tumor (TGCT). The study showed that among patients initially randomized to pimicotinib, improvements in symptoms and joint function were observed as early as Week 5, sustained through two years, and continued to improve over time. Tumor responses remained robust1 and durable,2 and the safety profile was consistent with previous analyses. The findings are being presented today in the Sarcoma poster session at the European Society for Medical Oncology (ESMO) Congress 2026 (Presentation # 3747P). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye